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M A J O R A R T I C L E
Risk Factors for Acquisition of Levofloxacin-
Resistant Streptococcus pneumoniae:
A Case-Control Study
P. L. Ho,1 W. S. Tse,3 Kenneth W. T. Tsang,2 T. K. Kwok,2 T. K. Ng,3 Vincent C. C. Cheng,1 and Robert M. T. Chan1
Departments of 1Microbiology and 2Medicine, Division of Infectious Diseases, Queen Mary Hospital, University of Hong Kong,
and 3Department of Clinical Pathology, Princess Margaret Hospital, Hong Kong, China
A case-control study was conducted to identify the risk factors associated with levofloxacin-resistant Strep-
tococcus pneumoniae (LRSP) colonization or infection. Twenty-seven case patients (patients with LRSP) were
compared with 54 controls (patients with levofloxacin-susceptible S. pneumoniae). Risk factors that were
significantly associated with LRSP colonization or infection, according to univariate analysis, included an older
age (median age, 75 years for case patients versus 72.5 years for controls), residence in a nursing home (odds
ratio [OR], 7.2), history of recent (OR, 4.6) and multiple (OR, 4.4) hospitalizations, prior exposure to fluoro-
quinolones (OR, 10.6) and b-lactams (OR, 8.6), presence of chronic obstructive pulmonary disease (COPD;
OR, 5.9), and nosocomial origin of the bacteria (OR, 5.7). Multivariate analysis showed that presence of COPD
(OR, 10.3), nosocomial origin of the bacteria (OR, 16.2), residence in a nursing home (OR, 7.4), and exposure
to fluoroquinolones (OR, 10.7) were independently associated with LRSP colonization or infection. Thus, a
distinct group of patients with COPD is the reservoir of LRSP.
A major issue in pneumococcal infection in recent years
is the emergence and global dissemination of multiply
resistant strains of Streptococcus pneumoniae. In many
countries, currently 140% of isolates are resistant to
penicillin [1–5]. Among the penicillin-resistant S. pneu-
moniae isolates, 60%–90% are also resistant to chlo-
ramphenicol, clindamycin, cotrimoxazole, erythromy-
cin, and tetracycline. In coincidence with this escalating
drug resistance problem among the pneumococci in
the 1990s was the launching of a number of new fluoro-
quinolones with enhanced activity against gram-posi-
tive bacteria. Generally speaking, this group of agents
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has good safety profiles and favorable pharmacokinetic
properties. Given these desirable characteristics of the
newer fluoroquinolones and the significance of peni-
cillin-resistant S. pneumoniae in community-acquired
pneumonia, the newer quinolones are being prescribed
with increasing frequency for initial treatment of res-
piratory tract infections [6, 7]. As the rate of use in-
creases, resistance to the newer fluoroquinolones will
likely rise. Indeed, in the past few years, fluoroquino-
lone-resistant S. pneumoniae have been reported from
many countries, although the prevalence still remains
low in general [1, 7–10]. In an attempt to understand
better the epidemiological and clinical aspects of fluoro-
quinolone-resistant S. pneumoniae, a retrospective,
multicenter study was conducted in Hong Kong, a re-
gion with a 5.5% rate of levofloxacin-resistant S. pneu-
moniae (LRSP) [11].
PATIENTS AND METHODS
Settings. This study was conducted at 3 hospitals
(A, B, and C) in Hong Kong. Hospitals A and C are
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acute regional medical centers, including a university hospital
with intensive care, burn, liver, kidney, and bone marrow trans-
plantation units. The remaining hospital (B) is a convalescent
institute. These hospitals serve approximately one-quarter of
the population of Hong Kong. The microbiology laboratories
of these hospitals handle clinical specimens from both inpa-
tients and outpatients.
Study design and patient description. This retrospective
study included an 18-month period from June 1998 through
November 1999. A case-control study was done to compare
the frequency of exposure and the features of case patients with
those of control patients and to identify and quantify potential
risk factors associated with LRSP colonization or infection.
Both case and control patients were identified by means of a
systematic review of the laboratory results in the microbiology
laboratories. Because both infected and colonized patients
might play a role in the transmission of LRSP, both patient
groups were considered to be case patients. A “case patient”
was defined as one who was either clinically infected with or
colonized by S. pneumoniae that was resistant to levofloxacin.
For instances of multiple isolations of LRSP from the same
patient, the initial isolation was used. One case patient was
matched with 2 control patients according to hospital location
(for all adults) and date of bacterial isolation. “Control patients”
were either clinically infected with or colonized by levofloxacin-
susceptible S. pneumoniae.
Patient records were reviewed, and relevant data were entered
onto predesigned forms. All diagnoses and underlying diseases
had been previously documented in the patient charts and were
independently verified by a clinician by use of predetermined
criteria. To identify the patients’ exposure to antibiotics during
hospital admissions and attendance at emergency departments
and outpatient clinics, the networked, computerized records in
the pharmacies were reviewed. The following data were ob-
tained for all patients: age, sex, type of ward, prior hospital-
ization, residence in a nursing home, underlying diseases, site
of bacterial isolation, status of bacterial isolation (infection or
colonization), infective syndrome–associated bacterial isola-
tion, origin of the infection or colonization (community- or
hospital-acquired), length of hospitalization, prior exposure to
antibiotics, and outcome (survival or death).
Microbiological data, including the date of initial isolation,
site of isolation, and antimicrobial susceptibilities, were col-
lected. During the study period, there were 1366 isolations of
S. pneumoniae from 1060 patients. LRSP was identified in 29
hospitalized patients. Medical records were available for 27 of
these patients.
Definition of terms. The “type of ward” (e.g., medical,
surgical, or orthopedic) was defined as the place where the
patient was staying on the day that the bacteria were isolated.
All past events and prior exposures were dated back from the
day of admission. “Prior hospitalization” was defined as any
inpatient treatment that lasted for 11 day in the 12 months
prior to admission. “Recent hospitalization” was defined as any
inpatient treatment that lasted for 11 day in the 6 weeks prior
to hospitalization. “Multiple hospitalizations” were defined as
13 admissions during the 12 months prior to hospitalization.
“Underlying diseases” included all those that might increase
patients’ predisposition to infection and adversely affect their
life expectancies. All diagnoses of chronic obstructive pulmo-
nary disease (COPD) were made by the clinicians in charge of
the patients and were confirmed by the investigators by use of
a combination of clinical and laboratory criteria, as described
elsewhere [12]. The site of bacterial isolation was categorized
as “respiratory,” “blood,” and “other.” Colonization was di-
agnosed when S. pneumoniae was isolated from sputum spec-
imens in the absence of clinical, laboratory, and/or radiological
features that were suggestive of infection. Infective syndromes
were determined according to a combination of criteria. “Pneu-
monia” was defined by the clinical, radiographic, and labora-
tory criteria described by the Centers for Disease Control and
Prevention [13]. “Acute exacerbation of COPD” was defined
as a worsening of clinical symptoms that included increases in
cough, sputum production, and dyspnea.
“Bacteremia” was defined as the isolation of S. pneumoniae in
>1 culture of blood specimens in association with clinical fea-
tures of sepsis. An interval of 48 h between the time of admission
and day that bacteria were isolated was used to define the origin
of infection or colonization as community-acquired (<48 h) or
hospital-acquired (148 h). “Prior exposure to antibiotics” was
defined as administration of any oral or parenteral antimicrobial
agent for 11 day. “Previous exposure to antibiotics” was cate-
gorized according to time (any exposure that lasted for 11 day
during the 6-week and 12-month intervals prior to admission)
and class of agents (fluoroquinolones, b-lactams, macrolides, and
other). The b-lactam/b-lactamase inhibitor combinations were
grouped under the term “b-lactams.”
Microbiological methods. S. pneumoniae was identified by
use of Gram’s stain, colony morphology, bile solubility, and
sensitivity to optochin. Susceptibility testing was done by use
of the disk diffusion method, according to the National Com-
mittee for Clinical Laboratory Standards [14]. Antibiotic disks
that included chloramphenicol (30 mg), cotrimoxazole (tri-
methoprim-sulfamethoxazole; 1.25/23.75 mg), erythromycin
(15 mg), levofloxacin (5 mg), and oxacillin (1 mg) were obtained
from commercial sources (BBL; Becton Dickinson). Initial
screening for reduced susceptibility to penicillin was done by
use of the oxacillin disk (1 mg). For those strains with oxacillin
zone diameters of <19 mm, the MIC of penicillin was deter-
mined by use of the Etest (AB Biodisk), performed according
to the manufacturer’s recommendations. For determination of
levofloxacin resistance, strains with zone diameters of <13 mm
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(n p 54) OR (95% CI) P
Age, ya 72.5 (62.3–78.3) 75 (70–85) — .01
Nursing home residence 14 (52) 7 (13) 7.2 (2.4–21.6) !.001
COPD 17 (63)b 12 (22) 5.9 (2.2–16.3) .001
Nosocomial origin 18 (66) 14 (26) 5.7 (2.1–15.6) .001
Interval from day of admission
to isolation of LRSP, da 7 (1–20) 1 (1–3) — !.001
No. of prior admissionsa 4 (2–7) 1 (0–3) — !.001
Recent hospitalization 16 (59) 13 (24) 4.6 (1.7–12.3) .003
Multiple hospitalization 15 (56) 12 (22) 4.4 (1.6–11.8) .004
Previous exposure to antibioticsc
Fluoroquinolones 8 (30)/14 (52) 0 (0)/5 (9) —/10.6 (3.2–34.7) !.001/!.001
b-Lactams 24 (89)/25 (93) 20 (37)/32 (59) 14.7 (3.9–55.4)/
8.6 (1.8–40)
!.001/.006
NOTE. Data are no. (%) of patients, unless otherwise indicated. COPD, chronic obstructive pulmonary disease; LRSP, lev-
ofloxacin-resistant S. pneumoniae.
a Median (interquartile range).
b Colonization in 3 patients.
c Exposure to antibiotic therapy during the 6 weeks prior to hospitalization/12 months prior to hospitalization.
(corresponding to an MIC of >8 mg/mL) were interpreted as
resistant. All 27 strains from the case patients had levofloxacin
zone diameters of !13 mm. The MICs of levofloxacin for 3
strains were confirmed to be 16 mg/mL by use of the National
Committee for Clinical Laboratory Standards broth microdi-
lution method [14].
Statistical analysis. Potential risk factors for colonization
or infection with LRSP were identified by means of univariate
analysis. Either the x2 test or Fisher’s exact test was used for
categorical variables. Continuous variables were tested by use
of Student’s t test or the Mann-Whitney U test. The 12 variables
that were significant in the univariate analysis and those var-
iables that could increase the risk of LRSP colonization or
infection from a clinical point of view were further tested by
means of logistic regression done by the use of the forward
conditional method. P ! .05 was considered to be statistically
significant. A statistical package (SPSS 10.0; SPSS Hong Kong)
was used for all analyses.
RESULTS
Of the 27 hospitalized patients with LRSP, 9 were identified
from hospital A, 6 from hospital B, and 12 from hospital C.
Sex and types of wards did not differ between the case patients
and the 54 control patients. Twenty-four case patients were
men, compared with 43 control patients. Types of wards (data
are presented for case vs. control patients) were mostly medical
(24/27 vs. 43/54) in both groups; the remaining wards were
surgical (1/24 vs. 8/54), orthopedic (2/24 vs. 1/54), and on-
cology (0/24 vs. 2/54). Case patients were slightly older than
controls. The overall median age of all patients was 73 years
(interquartile range, 65–80.5 years). In both groups, isolation
of S. pneumoniae was associated with a similar proportion of
infective syndromes, including acute exacerbation of COPD
(10/27 vs. 30/54), pneumonia (11/27 vs. 9/54), and respiratory
colonization (6/27 vs. 15/54). The median duration of hospital
stay was longer among the case patients (11 days [interquartile
range, 4–47 days]) than it was among the control patients (5.5
days [interquartile range, 2–20.1 days]; ). BacteremiaP p .05
occurred in 1 case patient and in 4 control patients. One control
with bacteremic pneumonia also had clinical evidence of men-
ingitis. Four (19.1%) of 21 patients with infection with LRSP
died, compared with 5 (12.8%) of 39 controls ( )P p .7
Potential risk factors for infection or colonization with LRSP
are shown in table 1. The following risk factors were signifi-
cantly different between groups, according to univariate anal-
ysis: age, residence in a nursing home, COPD, nosocomial or-
igin of bacteria, interval between day of admission and isolation
of LRSP, number of prior admissions, and recent and multiple
hospitalizations. The occurrences of other underlying diseases,
including malignancy (3/27 vs. 12/54) and heart (6/27 vs. 9/
54) and cerebral (9/27 vs. 8/54) diseases, were similar for case
patients and controls. Exposure to 2 antibiotic groups (fluoro-
quinolones and b-lactams) occurred significantly more fre-
quently among the case patients. In contrast, the groups did
not differ in terms of exposures to macrolides during both the
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6 weeks prior to admission (3/27 vs. 0/54) and 12 month prior
to admission (3/27 vs. 6/54).
Exposure to fluoroquinolones in the group of case patients
amounted to 27 treatment courses and 291 days, compared
with 7 courses and 55 days for the control group. The main
characteristics of the 14 case patients who had recent and/or
remote exposure to fluoroquinolones are summarized in table
2. Of note, 11 of the 14 patients had COPD. The most common
daily doses were 400 mg (range, 200–600 mg) for levofloxacin,
1000 mg (range, 400–1000 mg) for ciprofloxacin, and 600 mg
(range, 200–800 mg) for ofloxacin. Three case patients had
isolation of LRSP while they were receiving therapy with fluor-
oquinolones for pneumonia (patient 12, oral levofloxacin, 400
mg q.d.) or acute exacerbation of COPD (patient 13, oral levo-
floxacin 400 mg q.d.; patient 18, oral ciprofloxacin 500 mg
b.i.d.). All 3 patients who were treated with fluoroquinolones
and who were infected with LRSP had clinical failure. They
improved after treatment with iv vancomycin (patients 12 and
18) and high-dose oral ampicillin-sulbactam (patient 13).
The logistic regression model showed that presence of COPD
(OR, 10.3; 95% CI, 1.6–66.2; ), nosocomial origin ofP p .01
the bacteria (OR, 16.2; 95% CI, 2.1–122.2; ), residenceP p .007
in a nursing home (OR, 7.4; 95% CI, 1.5–35.1; ), andP p .01
exposure to a fluoroquinolone during the 12 months prior to
admission (OR, 10.7; 95% CI, 1.6–71.2; ) were factorsP p .01
that were independently associated with LRSP infection or col-
onization. Data regarding susceptibilities of the sputum isolates
to penicillin, erythromycin, cotrimoxazole, and chloramphen-
icol are shown in table 3. LRSP isolates were more likely than
levofloxacin-susceptible S. pneumoniae to have resistance to
penicillin and non–b-lactam agents.
DISCUSSION
Recognition of patients who have an increased risk of ex-
posure to LRSP is important in the battle against the epidemic
dissemination of these multiply resistant pneumococci. It is
believed that the global emergence of drug-resistant S. pneu-
moniae has occurred in stages and that those stages involved
selection of resistant mutants and clonal expansion [15]. This
study showed that risks of infection with LRSP are increased
among those who are institutionalized in nursing homes, those
who have hospital-acquired pneumococcal infection, those who
have received fluoroquinolones previously, and those who have
COPD as comorbidity. Prior treatment with a fluoroquinolone
is relevant because it provides the necessary selection pressure
for mutations. Because prolonged carriage of S. pneumoniae
can allow for persistence of early-step mutants that were in-
duced by multiple courses of fluoroquinolone treatment [16],
we chose to examine exposure to fluoroquinolones in the 12
months prior to admission. Our data demonstrated that the
majority of the case patients (63%) had COPD. This suggests
that elderly patients with COPD are the main reservoir of LRSP.
This situation is different from that of penicillin-resistant S.
pneumoniae, for which children are widely believed to be the
reservoir. In agreement with our observation, an increase in
resistance to fluoroquinolones, from !1% in 1995 to 13% in
1998, has been reported among older Canadians [9].
Our findings show that the presence of COPD in patients
who were treated with fluoroquinolones could play a role in
the selection of fluoroquinolone resistance. An examination of
some reports of previous studies might help to explain this
observation. The first explanation related to the limited anti-
pneumococcal activities of ciprofloxacin and ofloxacin. The
MIC90 values of both agents were 2–4 mg/mL in most previous
studies. Levofloxacin is the S-isomer of ofloxacin. Although it
is more active than ofloxacin, its MIC for pneumococci is only
2 times lower than that of ofloxacin. In Hong Kong, the MIC50
and MIC90 values of levofloxacin for pneumococci were 1 mg/
mL and 1.5 mg/mL, respectively [11]. For ofloxacin, the mean
sputum level of ofloxacin was 1.2 mg/mL after administration
of a 300-mg dose [17]. The levels that were reported for cip-
rofloxacin were 3.41 mg/L (mean peak level) and 1.11 mg/L
(mean trough level) when the drug was given at a dosage of
750 mg b.i.d. [18]. Data on the sputum level of levofloxacin
after the usual 500-mg dose are not available. After a single
oral dose of 200 mg, peak sputum levels of 4 mg/mL and 4.7
mg/mL were reported in 2 patients [19]. In this study, 9 of the
14 case patients with exposure to fluoroquinolones had received
ciprofloxacin and/or ofloxacin. Among the 8 case patients who
were treated with levofloxacin, the dosage was potentially sub-
optimal (!500 mg, given daily) in 15 of the 16 treatment
courses. Therefore, exposure to levels of these fluoroquinolones
that are below the MIC is to be expected in the sputum, leading
to de novo selection of resistant mutants. In vitro, resistant
mutants can be easily selected at a frequency of 1025 after
exposure of S. pneumoniae to subinhibitory concentrations of
most fluoroquinolones.
The next question to ask is whether these counts of pneu-
mococci are to be encountered in the airways of patients with
pneumococcal infections. In patients with COPD, the average
sputum count of S. pneumoniae was reported to be 107 cfu/
mL, during both the periods of exacerbation and remission
[16]. Notwithstanding these data, resistance that occurred in
S. pneumoniae isolates that persisted after fluoroquinolone
treatment has not been evaluated in clinical trials of treatment
of patients who have acute bacterial exacerbation of chronic
bronchitis [20–29]. In the study by Davies and Maesen [21]
on the effectiveness of levofloxacin in treatment of patients
with acute bacterial exacerbation of chronic bronchitis, a high
rate of treatment failure (13 [65%] of 20) was reported in
association with S. pneumoniae [21].
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Table 2. Summary of clinical data for 14 patients with levofloxacin-resistant Streptococcus pneumoniae (LRSP) and their
previous exposure to fluoroquinolones.











1, B None Ischemic heart disease,
chronic renal failure,
hypertension
07/99 Lvfx 1 10 (10)
5, B Recurrent aspiration Stroke, Parkinson’s
disease
10/99 Lvfx 1 10 (—)
11, C COPD Congestive heart failure,
ischemic heart disease
07/98 Cpfx, Lvfx 4 36 (—)
12, C COPD None 08/99 Cpfx, Lvfx 3 27 (25)
13, C COPD, old TB None 12/99 Lvfx 1 5 (5)
14, C COPD Ischemic heart disease 09/98 Ofx 1 4 (—)
15, C COPD, old TB Benign prostatic
hypertrophy
09/98 Lvfx 1 7 (7)
16, C COPD None 09/98 Cpfx, Lvfx 6 58 (10)
17, C COPD None 10/98 Cpfx, Ofx 2 24 (7)
18, C COPD, old TB None 10/98 Cpfx 2 34 (34)
21, A COPD None 04/99 Lvfx 2 14 (7)
24, A None Dementia, hypertension 08/99 Ofx 1 7 (—)
25, A COPD Ischemic heart disease,
hypertension
11/99 Ofx 1 10 (—)
26, A COPD, old TB Hypertension 11/99 Ofx 1 18 (—)
NOTE. COPD, chronic obstructive pulmonary disease; Cpfx, ciprofloxacin; Lvfx, levofloxacin; mo, month; Ofx, ofloxacin; TB, tuberculosis.
a Data are no. of days of treatment during 12 months prior to admission (no. of days of treatment during 6 weeks prior to admission).
Table 3. Comparison of resistance to agents other than fluor-








(n p 54) P
Penicillin 25/27 (92.5) 27/54 (50) !.001
Chloramphenicol 14/15 (93.3) 9/30 (30) !.001
Cotrimoxazole 16/16 (100) 17/30 (56.7) .002
Erythromycin 27/27 (100) 27/54 (50) !.001
Multiplea 17/17 (100) 14/33 (42.4) !.001
NOTE. Data are no. of nonsusceptible strains/total no. of strains tested (%).
a Nonsusceptible to >3 of above agents.
An alternative hypothesis to explain the link between fluoro-
quinolone resistance and COPD is that nosocomial spread of
pneumococci is biased toward the most vulnerable pa-
tients—those with COPD. During an interhospital outbreak of
infection with multidrug-resistant S. pneumoniae in The Neth-
erlands, COPD was identified as a major risk factor for acqui-
sition of multidrug-resistant pneumococci [30]. Results of staff
screening were negative. The authors concluded that patient-to-
patient spread was the most likely mechanism of dissemination.
After the implementation of several measures, including screen-
ing of patients with COPD for carriage of drug-resistant pneu-
mococci, pneumococcal eradication therapy, and barrier nursing
of those persons who tested positive for carriage in a separate
nursing room, the epidemic ceased immediately [30].
The case patients in our study were not epidemiologically
linked with regard to their nursing home residence, geographic
locations, and period of admission. However, the possibility
that case patients in our study were part of a complicated
interinstitutional outbreak cannot be excluded. Patients with
COPD who have been colonized with S. pneumoniae have been
reported to play a role in patient-to-patient transmission of
pneumococci [30]. During the study period, there were no
attempts to identify carriage of LRSP in the hospitalized patients
with COPD. Moreover, a preliminary analysis of 10 strains of
LRSP that we reported elsewhere revealed that they all shared
an indistinguishable DNA pattern, which was determined by
use of pulsed-field gel electrophoresis [31]. Prospective epi-
demiological studies are indicated to validate this outbreak hy-
pothesis. Meanwhile, isolation precautions, such as screening
of the patients with COPD and cohort nursing of those with
LRSP, are justified in the institutions that treat a high number
of patients who have strains with fluoroquinolone resistance.
Fluoroquinolone resistance among clinical isolates of pneu-
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mococci occurred mainly as a result of point mutations in the
topoisomerase genes [8]. For most fluoroquinolones, a single
mutation generally causes only a <8- to 16-fold increase in the
MIC. On the basis of this and other in vitro and vivo findings,
a therapeutic index (ratio of drug level at site of infection to
MIC) of 10–16 has been suggested to be required for prevention
of the emergence of resistant mutants during treatment with
fluoroquinolones [32–34]. The MIC breakpoint of levofloxacin
for the pneumococci was set at 2 mg/mL. On the basis of this
breakpoint, sputum levofloxacin levels of 20–32 mg/mL will be
required to prevent fluoroquinolone resistance in the case of
airway infection. Such levels are not reached in the sputum
after the currently recommended dose of 500 mg.
On the other hand, the therapeutic index for prevention of
resistance is reached in alveolar macrophages. In the study by
Andrews et al. [35], the mean alveolar macrophage level was
41.9 mg/mL after a single 500-mg oral dose of fluoroquinolones.
Alveolar concentration might be more relevant than sputum
level for pneumococcal pneumonia, although this is contro-
versial for the extracellular pathogens. In clinical trials, devel-
opment of resistance rarely occurred after treatment of com-
munity-acquired pneumonia [36]. Nonetheless, the fluoro-
quinolones appear to differ in their potentials for selection of
first-step mutants with mutations in the parC genes. Drugeon
et al. [37] examined 2 strains of S. pneumoniae and found that
the relative potential of levofloxacin is lower than that of cip-
rofloxacin, ofloxacin, and sparfloxacin. Interpretation of these
data, however, is difficult, because most studies have involved
only a small number of strains. The major clones of S. pneu-
moniae that are currently prevalent in various countries have
not yet been studied [38]. It is uncertain whether the potential
to yield resistant mutants depends on the strain. This is further
complicated by the use of different methodology for selection
of resistant mutants. Moreover, data are not available on this
topic for the newer fluoroquinolones that are more active
against pneumococci, such as moxifloxacin, clinafloxacin, and
gemifloxacin. Comparisons of the effects of different fluoro-
quinolones on clinical strains from different countries need to
be conducted by use of the same method.
The present study shows that pneumococcal resistance to
levofloxacin is associated with resistance to penicillin, chloram-
phenicol, cotrimoxazole, and erythromycin. In a previous study
of 181 pneumococci strains obtained from 7 hospitals in Hong
Kong, levofloxacin resistance was more common among strains
that were not susceptible to penicillin (8%) than it was among
penicillin-susceptible strains (0%) [11]. These findings differ
from those in reports from other countries, which found that
fluoroquinolone susceptibilities of pneumococci were indepen-
dent of the MIC of penicillin [39, 40]. In our study, the use
of a b-lactam was a risk factor for fluoroquinolone resistance
in the univariate analysis, but this risk factor disappeared in
the multivariate analysis. This finding suggests that the fluor-
oquinolones, rather than the b-lactams, provide the major se-
lective pressure for fluoroquinolone resistance. Therefore, the
emergence of fluoroquinolone resistance appears to be domi-
nated by fluoroquinolone use, but the long-term selection of
these multiresistant strains may well include selection with any
of the other agents to which they are resistant. In any case,
infection control measures and the judicious use of antibiotics
will remain major defenses against these multiply resistant
pneumococci. In children, conjugated pneumococcal vaccines
have been shown to be able to reduce carriage of vaccine se-
rotypes [41, 42]. Given that LRSP belongs to 2 of the vaccine
serotypes, 19F and 23F [31], studies of the roles of the con-
jugated vaccines, with regard to their ability to eliminate pneu-
mococcal carriage in patients with COPD, should be done now.
In conclusion, a distinct group of patients with COPD ap-
pears to be an important reservoir of LRSP in Hong Kong.
These LRSP isolates appeared to have emerged both de novo
after suboptimal use of fluoroquinolones and by means of per-
son-to-person transmission in hospitals or nursing homes. Use
of fluoroquinolones should be restricted for these patients who
are at increased risk of getting LRSP. Our findings call for
international attention and collaborative strategies to prevent
these strains from intercontinental dissemination.
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